Modified Vaccine for High Risk or Low Residual Melanoma Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

A2/4-1BBL melanoma vaccine

On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.

PROCEDURE

DNP sensititzation

"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."

DRUG

Cyclophosphamide

On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.

Trial Locations (1)

91120

RECRUITING

Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem

All Listed Sponsors
lead

Hadassah Medical Organization

OTHER